Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ampreloxetine for nOH in MSA
NCT05696717Phase 3Active, not recruiting
- Sponsor
- Theravance Biopharma, Inc.
- Start
- Jun 2023
- Primary completion
- Jan 2026
- Modality
- Small Molecules
- Countries
- 20
01
Overview
A Phase 3 trial of ampreloxetine in Neurogenic Orthostatic Hypotension (nOH), sponsored by Theravance Biopharma, Inc.. Started Jun 2023; status: active, not recruiting.
02
Drugs
ampreloxetine
03
Conditions
Neurogenic Orthostatic Hypotension (nOH)
Beyond the preview
Go deeper on NCT05696717.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05696717.